Skip to content
← Full study record

NCT00602667 · OUTCOME

Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
µmol/L
Interval / dispersion
Full Range
Time frame
42 hours from start of MTX

What was measured

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.

Analysis population: Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.

Groups in this outcome

Low-Risk Group

Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma

Intermediate-Risk Group

Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease

High-Risk Group

Patients with central nervous system (CNS) metastatic disease

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Low-Risk Group37
Intermediate-Risk Group93
High-Risk Group44

Reported measurements

Source class 1
Values in µmol/L · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Low-Risk Group0.49Not reported0.223.68Not reported
Intermediate-Risk Group0.57Not reported0.154.61Not reported
High-Risk Group0.61Not reported0.142.09Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.22
        upper Limit
        3.68
        value
        0.49
      2. group Id
        OG001
        lower Limit
        0.15
        upper Limit
        4.61
        value
        0.57
      3. group Id
        OG002
        lower Limit
        0.14
        upper Limit
        2.09
        value
        0.61
denoms
  1. counts
    1. group Id
      OG000
      value
      37
    2. group Id
      OG001
      value
      93
    3. group Id
      OG002
      value
      44
    units
    Participants
description
Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis.
dispersion Type
Full Range
groups
  1. description
    Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma
    id
    OG000
    title
    Low-Risk Group
  2. description
    Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease
    id
    OG001
    title
    Intermediate-Risk Group
  3. description
    Patients with central nervous system (CNS) metastatic disease
    id
    OG002
    title
    High-Risk Group
param Type
MEDIAN
population Description
Eligible patients who received methotrexate during induction cycle 1 and had samples collected for PK analysis.
reporting Status
POSTED
time Frame
42 hours from start of MTX
title
Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1
type
SECONDARY
unit Of Measure
µmol/L

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice